Catheter Precision
VTAK
9 hedge funds and large institutions have $125K invested in Catheter Precision in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
215,690% more capital invested
Capital invested by funds: $58 → $125K (+$125K)
200% more funds holding
Funds holding: 3 → 9 (+6)
4.1% more ownership
Funds ownership: 0% → 4.1% (+4.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$79.8K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$29.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$7.77K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.54K |
Top Sellers
VTAK Hedge Fund Activity: Q4 2025 in Review
9 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Catheter Precision (VTAK) for Q4 2025, worth a combined $125K — up 215,690% from $58 a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new VTAK positions and 0 closed out — a net gain of 6 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $79.8K.
- 9 institutional investors held Catheter Precision (VTAK) as of Q4 2025, up from 3 in Q3 2025.
- Funds reported $125K of Catheter Precision stock for Q4 2025, up 215,690% quarter-over-quarter.
- 6 funds opened new Catheter Precision positions in Q4 2025 and 0 closed out, a net change of +6 holders.
- The largest Catheter Precision buyer in Q4 2025 was Millennium Management, an estimated $79.8K added.
Based on aggregated 13F filings for Q4 2025.